P803: Plasma N-glycan biomarkers predict patient Response to Vedolizumab treatment for Crohn's DiseaseECCO’23 CopenhagenYear: 2023
Authors: Elgood Hunt, G.(1)*;Adams, A.(2);Senard, T.(1);Gardner, R.(1);Jonge, W.(3);Li Yim, A.(3);Noble, A.(2);Satsangi, J.(2);Joustra, V.(3);D'Haens, G.(3);Spencer, D.(1);
(1)Ludger, Development, Oxford, United Kingdom;(2)Oxford University, Experimental Medicine Division, Oxford, United Kingdom;(3)University Medical Centre, Inflammatory Bowel Disease Centre, Amsterdam, The Netherlands;
P804: Development and Validation of the Glasgow Exclusive Enteral Nutrition Index of Compliance (GENIE)ECCO’23 CopenhagenYear: 2023
Authors: Jatkowska, A.(1);White, B.(1);Nichols, B.(1);Svolos, V.(1);Gkikas, K.(1);Hansen, R.(2);Russell, R.K.(3);Gaya, D.(4);Brownson, E.(5);Seenan, J.P.(5);Milling, S.(6);MacDonald, J.(5);Gerasimidis, K.(1)*;
(1)University of Glasgow, Human Nutrition, Glasgow, United Kingdom;(2)Royal Hospital for Children, Department of Paediatric Gastroenterology, Glasgow, United Kingdom;(3)Royal Hospital for Children & Young People, Department of Paediatric Gastroenterology, Edinburgh, United Kingdom;(4)Glasgow Royal Infirmary, Department of Gastroenterology, Glasgow, United Kingdom;(5)Queen Elizabeth University Hospital, Department of Gastroenterology, Glasgow, United Kingdom;(6)University of Glasgow, School of Infection and Immunity, Glasgow, United Kingdom;
P805: Selnoflast, a potent NLRP3 inhibitor - results from a phase 1b experimental medicine study in patients with Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Klughammer, B.(1)*;Piali, L.(1);Nica, A.C.(1);Nagel, S.(1);Bailey, L.(2);Jochum, C.(3);Ignatenko, S.(4);Bläuer, A.(1);Danilin, S.(1);Gulati, P.(1);Hayward, J.(5);Scepanovic, P.(1);Retout, S.(1);Zhang, J.D.(1);Bhosale, S.(6);Sue-Ling, K.(7);Chong, C.F.(1);Christ, A.(1);
(1)F. Hoffmann-La Roche Ag, pRED, Basel, Switzerland;(2)Roche Products Limited, pRED, Welwyn Garden City AL7 3TW, United Kingdom;(3)Charité, Universitätsmedizin Berlin, Berlin, Germany;(4)Charité Research Organisation, GmbH, Berlin, Germany;(5)A4P Consulting Ltd, Discovery Park Innovation House, Sandwich, United Kingdom;(6)IQVIA RDS private limited, Statistics, Bangalore, India;(7)F. Hoffmann-La Roche Limited, pRED, Little Falls NJ, United States;
P806: Perianal Crohn's Disease (pCD): The outcome of 2nd line and 3rd line biologics in perianal Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Shani, U.(1)*;Ben Shabat, N.(1);Klang, E.(2);Ungar, B.(3);Ben-Horin, S.(3);Kopylov, U.(3);
(1)Sheba Medical Center, Department of Internal Medicine B, Ramat Gan, Israel;(2)Sheba Medical Center, ARC innovation center, Ramat Gan, Israel;(3)Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;
P807: Pregnancy and maternal outcomes in a cohort of patients with Inflammatory bowel disease: Encouraging data from a multi-disciplinary clinic in a tertiary centerECCO’23 CopenhagenYear: 2023
Authors: Avni Biron, I.(1,2)*;Hayat, L.(1);Ollech, J.E.(1,2);Banai-Eran, H.(1,2);Narkis, B.(2,3);Houri, O.(2,3);Pauker, M.H.(1,2);Shay, V.(1);Dotan, I.(1,2);Hadar, E.(2,3);Yanai, H.(1,2);
(1)Rabin Medical Center, Division of Gastroenterology, Petah-Tikva, Israel;(2)Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel;(3)Rabin Medical Center, Helen Schneider Hospital for Women, Petah-Tikva, Israel;
P809: The impact of different treatment strategies in newly diagnosed patients with Crohn's Disease: a multicentre studyECCO’23 CopenhagenYear: 2023
Authors: Revés, J.(1)*;Morão, B.(1);Montanaro, G.(2);Sciberras, N.(2);Bravo, A.C.(1);Glória, L.(1);Ellul, P.(2);Torres, J.(1);
(1)Hospital Beatriz Ângelo, Gastroenterology Department, Loures, Portugal;(2)Mater Dei Hospital, Division of Gastroenterology, Msida, Malta;
P810: Association between Ustekinumab Trough Levels, Serum IL-22 and Oncostatin M Levels with Clinical and Biochemical Outcomes in Patients With Crohn's Disease.ECCO’23 CopenhagenYear: 2023
Authors: Bertin, L.(1)*;Gubbiotti, A.(2);Buda, A.(3);Zingone, F.(1);Savarino, E.V.(1);Barberio, B.(1);
(1)Azienda Ospedale Università Padova, Gastroenterology Unit- Department of Surgery- Oncology and Gastroenterology, Padova, Italy;(2)Azienda Ospedale Università Padova, Endoscopy Unit, Padova, Italy;(3)S. Maria del Prato Hospital, Gastroenterology Unit- Department of Gastrointestinal Oncological Surgery, Feltre, Italy;
P811: Combination biological or small molecule therapy in patients with refractory inflammatory bowel disease: a multicenter Brazilian experienceECCO’23 CopenhagenYear: 2023
Authors: Feitosa, F.(1)*;Parra, R.(2);Queiroz, N.(3);Flores, C.(4);Schiavetti, B.(5);Azevedo, M.(6);Porto Alegre Rosa, C.(7);Chebli, L.(8);Chebli, J.(8);
(1)Centro Médico do Hospital Aliança Rede D'Or São Luiz, Gastroenterologia, Salvador, Brazil;(2)HCFMRP-USP, Surgery and Anatomy, Ribeirão Preto, Brazil;(3)IBD Center, Gastroenterologia, Curitiba, Brazil;(4)Reference Center in Crohn and Colitis, Digestive System Institute, Porto Alegre, Brazil;(5)Prefeitura de Santos, Américas Vitória, Santos, Brazil;(6)Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Gastroenterologia, São Paulo, Brazil;(7)Rede Dor, Hospital São Luiz, Rio de Janeiro, Brazil;(8)IBD Center, Federal University of Juiz de Fora UFJF, Juiz de Fora, Brazil;
P812: Fluorescently labelled vedolizumab identified macroscopic and microscopic mucosal drug distribution in patients with inflammatory bowel diseaseECCO’23 CopenhagenYear: 2023
Authors: Van Der Waaij, A.(1)*;Gabriëls, R.(1);Linssen, M.(1);Volkmer, P.(1);Robinson, D.(2);Hermoso, M.(1);Karrenbeld, A.(3);Festen, E.(1);Dijkstra, G.(1);Kats-Urgulu, G.(1);Nagengast, W.(1);
(1)UMCG, Gastroenterology and Hepatology, Groningen, The Netherlands;(2)Erasmus MC Cancer Institute, Department of Otorhinolaryngology and Head and Neck Surgery, Rotterdam, The Netherlands;(3)UMCG, Pathology, Groningen, The Netherlands;
P813: A scoping review on the assessment and improvement of health-related physical fitness in patients with Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Demers, K.(1,2,3)*;Bak, M.T.J.(4);Bongers, B.C.(2,5);de Vries, A.C.(4);Jonkers , D.M.A.E.(2);Pierik , M.J.(2,3);Stassen, L.P.S.(1,2);
(1)Maastricht University Medical Center+, Department of Surgery, Maastricht, The Netherlands;(2)Maastricht University, School of Nutrition and Translational Research in Metabolism NUTRIM, Maastricht, The Netherlands;(3)Maastricht University Medical Center+, Division of Gastroenterology and Hepatology - Department of Internal Medicine, Maastricht, The Netherlands;(4)Erasmus University Medical Center Rotterdam, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(5)Maastricht University, Department of Epidemiology - Care and Public Health Research Institute CAPHRI, Maastricht, The Netherlands;
P814: Clinical trial design in Crohn's disease: interpreting future endpoints based on post hoc analyses of the vedolizumab phase 3 trials GEMINI 2 and VISIBLE 2ECCO’23 CopenhagenYear: 2023
Authors: Khan, R.M.Q.(1);Schwartz, D.A.(2);Sands, B.E.(3);Hanauer, S.(4);Uddin, S.(1);Mukherjee, R.(1);Lichtenstein, G.(5)*;
(1)Takeda Pharmaceuticals U.S.A.- Inc., US Medical, Lexington- MA, United States;(2)Vanderbilt University Medical Center, Department of Gastroenterology, Nashville- TN, United States;(3)The Mount Sinai Hospital- Feinstein IBD Clinical Center- Icahn School of Medicine at Mount Sinai, The Henry D Janowitz Division of Gastroenterology, New York- NY, United States;(4)Northwestern University Feinberg School of Medicine, Division of Gastroenterology, Chicago- IL, United States;(5)University of Pennsylvania, School of Medicine, Philadelphia- PA, United States;
P815: Diet, nutrition, and the multidisciplinary approach in adults with Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Playford, C.(1)*;Asghar, Z.(1);Armstrong, S.(1);Ngomba, R.(2);Rochford, A.(3);
(1)University of Lincoln, Health and Social Care, Lincoln, United Kingdom;(2)University of Lincoln, Pharmacy, Lincoln, United Kingdom;(3)Royal Free London Hospitals, NHS Foundation Trust, London, United Kingdom;
P816: The efficacy of an over the counter multivitamin and mineral supplement to prevent opportunistic infections in patients with inflammatory bowel disease in remission.ECCO’23 CopenhagenYear: 2023
Authors: Laheij, R.(1)*;van Knippenberg, Y.(1);Heil, A.(1);Mannaerts, B.(1);Bruin, K.(1);Lutgens, M.(1);Sikkema, M.(1);de Wit, U.(1);Laheij, R.(1);
(1)Elisabeth-Tweesteden Hospital, Department of Gastroenterology and Hepatology, Tilburg, The Netherlands;
P817: Symptoms of COVID-19 in Patients with Immune Mediated Inflammatory DiseasesECCO’23 CopenhagenYear: 2023
Authors: Schlosser, T.(1)*;Krasselt, M.(2);Elsing, L.(1);Hecker, M.(1);Holler, B.(1);Hoffmeister, A.(1);
(1)University Medical Centre Leipzig, Department of Oncology- Gastroenterology- Hepatology- Pulmonology and Infectious Diseases- Division of Gastroenterology, Leipzig, Germany;(2)University Medical Centre Leipzig, Department of Endocrinology- Nephrology and Rheumatology- Division of Rheumatology, Leipzig, Germany;
P818: Survival of ustekinumab treatment based on concomitant immunomodulator useECCO’23 CopenhagenYear: 2023
Authors: García Ramírez, L.(1)*;Suárez Ferrer, C.(2);Rueda Garcia, J.L.(2);Martín-Arranz, E.(2);Poza Cordón, J.(2);Sánchez-Azofra, M.(2);Martin-Arranz, M.D.(3);
(1)Grupo de enfermedades inmunomediadas gastrointestinales y otras patologías digestivas. Instituto de Investigación Sanitaria del Hospital Universitario La Paz – IdiPAZ- Madrid- España.- Fundación para la Investigación Biomédica- Hospital Universitario La Paz- Madrid- Spain- Madrid- Spain., Gastroenterology, madrid, Spain;(2)Grupo de enfermedades inmunomediadas gastrointestinales y otras patologías digestivas. Instituto de Investigación Sanitaria del Hospital Universitario La Paz – IdiPAZ- Madrid- España.- Gastroenterology Department. Hospital Universitario La Paz- Madrid- Spain- Madrid- Spain., Gastroenterology, Madrid, Spain;(3)Grupo de enfermedades inmunomediadas gastrointestinales y otras patologías digestivas. Instituto de Investigación Sanitaria del Hospital Universitario La Paz – IdiPAZ- Madrid- España.- Gastroenterology Department. Hospital Universitario La Paz- Madrid- Spain. Faculty of Medicine. Universidad Autónoma de Madrid- Madrid- Spain, Gastroenterology, Madrid, Spain;
P820: Comparison of three nutritional screening tools with the new GLIM criteria for malnutrition among definitive and elective surgery Crohn's patients in ChinaECCO’23 CopenhagenYear: 2023
Authors: Zhao, Z.(1)*;Chen, C.(1);Li, Y.(1);Ye, X.(1);Zhu, W.(1);
(1)Jinling Hospital- Medical School of Nanjing University, Research Institute of General Surgery, Nanjing, China;Research institute of General Surgery, Jinling Hospital, Medical School of Nanjing University
P822: The negative impact of mental health comorbidity in children and young adults with inflammatory bowel disease: a UK population-based cohort studyECCO’23 CopenhagenYear: 2023
Authors: Cooney , R.(1);Barrett, K.(2);Russell, R.K.(3)*;
(1)University Hospitals Birmingham NHS Foundation Trust, GI Medicine, Birmingham, United Kingdom;(2)New Road Surgery, 166 New Road- Croxley Green-, Rickmansworth, United Kingdom;(3)Royal Hospital for Children & Young People, Department of Paediatrics and Gastroenterology, Edinburgh, United Kingdom;
